<DOC>
	<DOCNO>NCT00432380</DOCNO>
	<brief_summary>This study provide data immune response safety GSK Biologicals ' HRV liquid vaccine give along routine infant immunization Philippines .</brief_summary>
	<brief_title>A Study Evaluate Immune Response Safety Two Doses GSK Biologicals ' HRV Liquid Vaccine Healthy Infants .</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infant , include , 510 week age time first dose HRV liquid vaccine placebo . Birth weight subject &gt; 2000 gram . Written inform consent obtain parent guardian subject . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol except DTPw , HBV OPV vaccine within 14 day dose HRV liquid vaccine placebo end 14 day . BCG administer birth accord local EPI . Concurrently participate another clinical study , time study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component HRV liquid vaccine placebo . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>5 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Placebo</keyword>
	<keyword>Double blind</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Randomized</keyword>
	<keyword>Oral live attenuate human rotavirus liquid vaccine</keyword>
</DOC>